Cite

    Braun, J. et al. (2008). Persistent clinical efficacy and safety of anti-tumour necrosis factor α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Annals of the rheumatic diseases. 67 (3), pp. 340-345. [Online].